Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CPM Demands Separate Ministry for Pharma Sector (India)

This article was originally published in PharmAsia News

Executive Summary

In a letter to Indian Prime Minister Manmohan Singh, Communist Party of India (Marxist) leader Sitaram Yechury has asked the government to form a separate ministry for the sector. The Indian pharma sector currently comes under different regulatory bodies of various ministries, a situation that Yechury says has hampered the growth of the estimated $12 billion industry. The Department of Chemicals and Fertilisers deals with issues relating to drugs and pricing, while product usage and regulation comes under the Ministry of Health and Drugs Controller General of India. The Department of Science and Technology regulates research and development, while pharma education is dealt with by the Ministry of Human Resource and Development and Ministry of Chemicals and Fertilisers. (Click here for more

You may also be interested in...



Warning Letter Close-Outs – October 2020

The US FDA issued only one device-related close-out letter in October.

Compounding Pharmacies Sue FDA For Conflating Out-Of-State Dispensing And Distribution In MOU

Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.

What COVID Spotlight Means For Pharma – In Their Own Words

Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem. 

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel